A first update on mapping the human genetic architecture of COVID-19 [PDF]
, 2022 Matters arising from: Mapping the human genetic architecture of COVID-19 Original Article published on 08 July 2021 https://www.nature.com/articles/s41586-021-03767-xThe COVID-19 pandemic continues to pose a major public health threat, especially in ...
COVID-19 Host Genetics Initiative
core +7 more sources
a case–case study based on electronic health records [PDF]
, 2023 Funding Information: The acquisition of sequencing equipment and reagents used in this study by the Instituto Nacional de Saúde Doutor Ricardo Jorge was partially funded by the HERA project (grant no. 2021/PHF/23776), supported by the European Commission
PT COVID-19 group
core +1 more source
results from an international survey of people with rheumatic diseases [PDF]
, 2021 Funding Information: We would like to thank all the clinicians, health-care providers, and patient organisations who helped to develop and disseminate this survey. A full list of all the contributors can be found in the appendix (pp 44?45).
COVID-19 Global Rheumatology Alliance
core +1 more source
Is it really time to ditch the mask? [PDF]
, 2022 publishersversionpublishe
ASPHER COVID-19 Task Force
core +1 more source
A proteomic survival predictor for COVID-19 patients in intensive care [PDF]
, 2022 © 2022 Demichev et al. This is an open access article distributed under the terms of the Creative Commons Attribution License. https://creativecommons.org/licenses/by/4.0/Global healthcare systems are challenged by the COVID-19 pandemic.
PA-COVID-19 Study group
core +1 more source
The Your COVID-19 risk assessment tool and the accompanying open access data and materials repositories [PDF]
, 2022 In March 2020, the Your COVID-19 Risk tool was developed in response to the global spread of SARS-CoV-2. The tool is an online resource based on key behavioural evidence-based risk factors related to contracting and spreading SARS-CoV-2.
Godinho, Cristina +1 more
core +1 more source
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. [PDF]
, 2022 Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete description of specific immune biomarkers. We present here a comprehensive multi-omic blood atlas for patients with varying COVID-19 severity in an integrated ...
COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium +1 more
core +1 more source
COVID‐19 and Inequalities* [PDF]
Fiscal Studies, 2020 AbstractThis paper brings together evidence from various data sources and the most recent studies to describe what we know so far about the impacts of the COVID‐19 crisis on inequalities across several key domains of life, including employment and ability to earn, family life and health.
Blundell, Richard +3 more
openaire +5 more sources
Needs assessment and impact of COVID-19 on pharmacy professionals in 31 commonwealth countries [PDF]
, 2020 Funding The study was approved by the Commonwealth Pharmacists Association Trus‑ tees and funded within CPA funds. There was no specifc grant from funding agencies in the public, commercial, or not-for-proft sectors.
C. P. A. COVID-19 Action Team
core +1 more source
Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients [PDF]
, 2021 Introduction: A growing evidence suggests that immune dysregulation and thrombotic phenomena are key features in the pathophysiology of COVID-19.
Astigarraga Aguirre, María Iciar +1 more
core +1 more source